Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: Results from a 6-month, multicenter, open study

Journal of Clinical Psychiatry

Volumn 62, Issue 10, 2001, Pages 818-825

  Vieta, E ^a   Goikolea, J M ^a   Corbella, B ^a   Benabarre, A ^a   Reinares, M ^a   Martinez G ^a   Fernandez A ^a   Colom, F ^a   Martinez Aran A ^a   Torrent, C ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CARBAMAZEPINE; HALOPERIDOL; LITHIUM; RISPERIDONE; VALPROIC ACID; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DYSARTHRIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; HAMILTON SCALE; HUMAN; HYPOTENSION; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; MANIC DEPRESSIVE PSYCHOSIS; MULTICENTER STUDY; NEGATIVE SYNDROME; PRIORITY JOURNAL; SCHIZOIDISM; SCORING SYSTEM; TARDIVE DYSKINESIA; TREATMENT OUTCOME; VERTIGO; VOMITING; WEIGHT GAIN;

EID: 0035192351     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v62n1011     Document Type: Article

References (50)

1. NIMH workshop report on treatment of bipolar disorder
2. Long-term treatment of mood disorders in schizophrenia
3. Copharmacy strategies for bipolar disorder
4. Long term treatment of bipolar disorder
5. The treatment of bipolar disorder: Current limitations and future prospects
6. Risperidone in the treatment of schizophrenia
7. Risperidone: Clinical safety and efficacy in schizophrenia
8. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients
9. Risperidone: A new, novel (and better?) antipsychotic
10. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American studies
11. Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: A case series
12. Risperidone in the treatment of affective illness and obsessive compulsive disorder
13. Risperidone therapy in treatment-refractory acute bipolar and schizoaffective mania
14. Risperidone in the treatment of mania
15. Acute treatment of bipolar disorder with adjunctive risperidone in outpatients
16. Treatment of refractory rapid cycling bipolar disorder with risperidone
17. Risperidone compared with both lithium and haloperidol in mania: A double-blind randomised controlled study
18. Safety and efficacy of risperidone versus placebo as add-on therapy to mood-stabilizers in the treatment of manic phase of bipolar disorder
19. Safety and efficacy of risperidone as combination therapy for the manic phase of bipolar disorder: Preliminary findings of a randomized, double-blind study (RIS-INT-46)
20. 2-adrenoceptor antagonism
21. Risperidone inhibits 5-hydroxytryptaminergic neuronal activity in the dorsal raphe nucleus by local release of 5-hydroxytryptamine
22. Efficacy and safety of risperidone in the treatment of schizoaffective disorder: Results from a large, multicentre surveillance study
23. Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder
24. A rating scale for mania: Reliability, validity, and sensitivity
25. Development of a rating scale for primary depressive illness
26. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia
27. The UKU Side Effect Rating Scale: A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of adverse events in neuroleptic-treated patients
28. Factors associated with maintenance antipsychotic treatment of patients with bipolar disorder
29. Practice guideline for the treatment of patients with bipolar disorder
30. Outcome in mania: A 4-year follow-up of 75 patients utilizing survival analysis
31. A clinical evaluation of risperidone in the treatment of schizophrenia: A 10-week, open-label, multicenter study
32. Extrapyramidal signs and symptoms in first-episode schizophrenia: Response to low-dose risperidone
33. Extrapyramidal symptoms in patients treated with risperidone
34. Pharmacokinetics and drug interactions: Update for new antipsychotics
35. Risperidone and cytochrome P450 3A
36. Lack of effect of amitryptyline on risperidone pharmacokinetics in schizophrenic patients
37. No effect of citalopram on plasma levels of clozapine, risperidone and their active metabolites in patients with chronic schizophrenia
38. Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders
39. Tardive dyskinesia as a life-threatening illness
40. Neurologic symptoms in pharmacotherapy of the psychoses
41. Tardive dyskinesia: Prevalence, incidence, and risk factors
42. Why do schizophrenic patients refuse to take their drugs?
43. High exposure to neuroleptics in bipolar patients: A retrospective review [CME]
44. Tardive dyskinesia in bipolar affective disorder
45. Tardive dyskinesia
46. Drug safety: Experience with risperidone
47. Alteration in the recommended dosing schedule for risperidone
48. Does evidence from clinical trials in psychopharmacology apply in clinical practice?